CPHOA Stock Overview
Engages in the development, cultivation, and distribution of recreational and medical cannabis products in Europe, Canada, Australia, and the Asia Pacific. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Creso Pharma Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.002 |
| 52 Week High | AU$0.029 |
| 52 Week Low | AU$0.002 |
| Beta | 2.61 |
| 1 Month Change | 0% |
| 3 Month Change | 0% |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -98.26% |
Recent News & Updates
Recent updates
Shareholder Returns
| CPHOA | AU Pharmaceuticals | AU Market | |
|---|---|---|---|
| 7D | 0% | 2.1% | 0.2% |
| 1Y | n/a | -26.6% | 7.5% |
Return vs Industry: Insufficient data to determine how CPHOA performed against the Australian Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how CPHOA performed against the Australian Market.
Price Volatility
| CPHOA volatility | |
|---|---|
| CPHOA Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 11.4% |
| Market Average Movement | 9.3% |
| 10% most volatile stocks in AU Market | 16.9% |
| 10% least volatile stocks in AU Market | 4.0% |
Stable Share Price: CPHOA has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine CPHOA's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | n/a | Will Lay | melodiolglobalhealth.com |
Creso Pharma Limited develops, registers, and commercializes pharmaceutical-grade cannabis, and hemp-based nutraceutical products and treatments for human and animal health in Europe, the Middle East, North America, and the Asia Pacific. The company develops and commercializes therapeutic products; and cultivates, processes, and sells cannabis products, as well as supplies cannabis retail products. Its products include anibidiol, a complementary feed product for companion animals; cannaQIX, a nutraceutical product containing hemp oil extract, and vitamins and zinc that reduces stress and supports psychological and nervous functions; and topical and skin care products, which include cannaDOL, a CBD-based topical gel associated with a mixture of cooling and warming essential oils.
Creso Pharma Limited Fundamentals Summary
| CPHOA fundamental statistics | |
|---|---|
| Market cap | AU$31.85m |
| Earnings (TTM) | -AU$18.15m |
| Revenue (TTM) | AU$7.53m |
Is CPHOA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CPHOA income statement (TTM) | |
|---|---|
| Revenue | AU$7.53m |
| Cost of Revenue | AU$6.10m |
| Gross Profit | AU$1.43m |
| Other Expenses | AU$19.58m |
| Earnings | -AU$18.15m |
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.0086 |
| Gross Margin | 18.95% |
| Net Profit Margin | -241.13% |
| Debt/Equity Ratio | 0% |
How did CPHOA perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2023/02/26 09:01 |
| End of Day Share Price | 2022/11/29 00:00 |
| Earnings | 2022/06/30 |
| Annual Earnings | 2021/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Melodiol Global Health Limited is covered by 0 analysts. of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.